The Filing Desk

Roivant Sciences vs Whitehawk Therapeutics

Roivant Sciences ROIV · Whitehawk Therapeutics WHWK · Biotechnology

Roivant Sciences reported revenue of $8 million in fiscal 2025, 1.2 times Whitehawk Therapeutics' $7 million in fiscal 2025. Roivant Sciences' revenue fell 71.6% in its latest year, and Whitehawk Therapeutics' fell 72.5%. Roivant Sciences had an operating margin of -6235.7%, against -1601.1% at Whitehawk Therapeutics. Free cash flow was −$759 million at Roivant Sciences and −$98 million at Whitehawk Therapeutics. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.

Side by side

Roivant SciencesWhitehawk Therapeutics
Latest fiscal yearFY2025, Mar 31, 2026FY2025, Dec 31, 2025
Revenue$8M$7M
Revenue growth−71.6%−72.5%
Revenue growth a year, last 5 years−19.0%−12.7%
Gross margin—89.4%
Operating margin−6,235.7%−1,601.1%
Net margin−3,629.2%−288.3%
Free cash flow−$759M−$98M
Free cash flow margin−9,183.5%−1,371.4%
Return on capital−62.6%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−4.3%129.0%
Last close$38.96$3.12
P/E at the last close——
Insider trades, last 12 monthssold $602.3 millionsold $2.6 million
Piotroski F-score1 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Roivant SciencesWhitehawk Therapeutics
Operating margin
Percent of revenue
Roivant SciencesWhitehawk Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Roivant SciencesWhitehawk Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Roivant Sciences and Whitehawk Therapeutics pages.